Pdt Partners, LLC Morphic Holding, Inc. Transaction History

Pdt Partners, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	SELL	$26.12 - $34.07 $905,397 - $1.18 Million	-34,663 Reduced 56.7%	26,474 $901,000
Q1 2024 May 15, 2024	BUY	$26.64 - $40.31 $1.43 Million - $2.16 Million	53,535 Added 704.22%	61,137 $2.15 Million
Q4 2023 Feb 14, 2024	SELL	$19.95 - $31.0 $691,068 - $1.07 Million	-34,640 Reduced 82.0%	7,602 $219,000
Q3 2023 Nov 14, 2023	BUY	$21.33 - $59.42 $166,032 - $462,525	7,784 Added 22.59%	42,242 $967,000
Q2 2023 Aug 14, 2023	BUY	$34.33 - $62.11 $1.18 Million - $2.14 Million	34,458 New	34,458 $1.98 Million
Q1 2022 May 16, 2022	SELL	$36.25 - $52.02 $189,261 - $271,596	-5,221 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$43.27 - $65.72 $225,912 - $343,124	5,221 New	5,221 $247,000

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.